Please login to the form below

Not currently logged in
Email:
Password:

First new COPD inhaler in 8 years launches

Novartis has launched the Onbrez Breezhaler (indacaterol), a once-daily LABA for use in Chronic Obstructive Pulmonary Disease (COPD), in the UK

The Onbrez Breezhaler (indacaterol), a new 24-hour once-a-day drug for use in Chronic Obstructive Pulmonary Disease (COPD), has been launched in the UK by Novartis. The long-acting beta agonist (LABA) is the first new COPD treatment to be introduced to the UK for eight years and is the first 24-hour once-daily COPD treatment to be available.

The European Medicines Agency (EMA) granted indacaterol an EU-wide licence in November 2009, based on the results of clinical trials in over 2,000 patients. These trials showed that indacaterol provided bronchodilation within five minutes and this effect lasted for 24 hours. This resulted in a clinically significant improvement in breathlessness at six months versus placebo.

Dr Steve Holmes, chair of the Primary Care Respiratory Society and a member of the British Thoracic Society Education Committee, commented: "This new treatment is great news as it offers a once daily treatment for people with COPD suffering from breathlessness. The early research shows significant improvements in patients' quality of life."

Indacaterol is a COPD maintenance therapy and is not for use either as a reliever or to treat asthma.

11th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics